Recent Updates
Recently added Catalysts
MDGL Positive Sentiment Score: 75/100

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

Thursday, November 2, 2023 1 min read
Key Takeaway: Madrigal Pharmaceuticals (NASDAQ: MDGL) has announced its participation in three upcoming investor conferences, including the UBS Biopharma Conference and the Piper Sandler Healthcare Conference. The management team will engage in fireside chats at these events, which will be available for live streaming and later replays. This initiative underscores Madrigal's continued efforts in the biopharmaceutical sector, especially concerning the treatment of nonalcoholic steatohepatitis (NASH). Their lead candidate, resmetirom, aims to address key underlying causes of the disease.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in three major investor conferences demonstrates strong industry engagement.
  • Webcasting of the events enhances accessibility for investors.
  • Madrigal's focus on NASH showcases their commitment to addressing a significant unmet medical need.

Full Press Release Details

CONSHOHOCKEN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in fireside chats at three upcoming investor conferences:
UBS Biopharma Conference 2023
5:00 pm ET on Wednesday, November 8, 2023.
6th Annual Evercore ISI HealthCONx Conference
3:00 pm ET on Wednesday, Nov 29, 2023.
Piper Sandler 35th Annual Healthcare Conference
1:00 pm ET on Thursday, November 30, 2023.
The fireside chats will be webcast and archived recordings will be available for replay in the Investors section of the Madrigal website after the events.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a liver-directed oral therapy that is designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.
Alex Howarth, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com

Tags

Frequently Asked Questions

What conferences will Madrigal Pharmaceuticals attend?

Madrigal Pharmaceuticals will participate in the UBS Biopharma Conference, Evercore ISI HealthCONx Conference, and Piper Sandler Healthcare Conference.

When is the UBS Biopharma Conference?

The UBS Biopharma Conference is scheduled for 5:00 pm ET on November 8, 2023.

What is Madrigal's lead candidate for NASH?

Madrigal's lead candidate for NASH is resmetirom, an oral therapy targeting key disease causes.

Where can I access the webcast of the conferences?

The webcasts and archived recordings will be available in the Investors section of Madrigal's website.

What is nonalcoholic steatohepatitis (NASH)?

NASH is a liver disease with significant unmet medical needs, which Madrigal aims to address.

Tags: MDGL Viatris Investor Conferences Healthcare Madrigal Pharmaceuticals NASH investor conferences resmetirom
Last updated: Nov 2, 2023